BTIG analyst Ryan Zimmerman lowered the firm’s price target on Stryker (SYK) to $403 from $416 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the MedTech space. The sector had been seen as a safe haven, but quarterly results will matter less than a company’s ability to navigate ahead, the analyst tells investors in a research note. Between a frenetic trade war largely now directed at China to cuts at many federal healthcare agencies, investors will want answers which companies may not be able to provide, and this may weigh on sentiment, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target lowered to $390 from $413 at Truist
- Strategic Divestiture and Growth Focus: Stryker’s Buy Rating Justified
- Strategic Acquisition of Inari Medical Positions Stryker for Long-Term Growth Despite Short-Term Margin Impact
- Stryker’s Strong Market Position and Growth Prospects Justify Buy Rating
- Penumbra initiated with a Buy at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue